These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 78220)

  • 1. Compensating the drug victim.
    Lancet; 1978 Jul; 2(8079):26. PubMed ID: 78220
    [No Abstract]   [Full Text] [Related]  

  • 2. Unforeseeable adverse drug reactions: who should pay?
    Loveland D
    Med Law; 1985; 4(4):327-36. PubMed ID: 4046760
    [No Abstract]   [Full Text] [Related]  

  • 3. Compensation for drug injury: two solutions to an insoluble problem.
    Smith R
    Br Med J (Clin Res Ed); 1981 May; 282(6276):1610-2. PubMed ID: 6786584
    [No Abstract]   [Full Text] [Related]  

  • 4. Compensation for drug injury. Problems both sides of the Atlantic.
    Smith R
    Br Med J (Clin Res Ed); 1981 May; 282(6274):1443-5. PubMed ID: 6784859
    [No Abstract]   [Full Text] [Related]  

  • 5. Crying wolf on drug safety.
    Br Med J (Clin Res Ed); 1982 Jan; 284(6311):219-20. PubMed ID: 6799107
    [No Abstract]   [Full Text] [Related]  

  • 6. Addressing Pharmaceutical Injuries: The US Landscape.
    Bakker C; Honig N
    Clin Pharmacol Ther; 2018 Mar; 103(3):384-385. PubMed ID: 28850676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compensation for unforeseen adverse drug reactions.
    Lancet; 1977 Apr; 1(8015):788. PubMed ID: 66578
    [No Abstract]   [Full Text] [Related]  

  • 8. A regulatory view of the Medicines Act in the United Kingdom.
    Andrews PA; Thompson GM; Ward C
    J Clin Pharmacol; 1984 Jan; 24(1):6-18. PubMed ID: 6368615
    [No Abstract]   [Full Text] [Related]  

  • 9. The pharmaceutical industry: research and responsibility.
    Peart WS
    Lancet; 1980 Aug; 2(8192):465-6. PubMed ID: 6106108
    [No Abstract]   [Full Text] [Related]  

  • 10. Unwanted drug effects: whose responsibility?
    Lancet; 1979 Jul; 2(8132):21. PubMed ID: 87894
    [No Abstract]   [Full Text] [Related]  

  • 11. Product liability in respect of drugs.
    Diamond AL; Laurence DR
    Br Med J (Clin Res Ed); 1985 Feb; 290(6465):365-8. PubMed ID: 3917823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Settlement of the benoxaprofen case.
    Dyer C
    Br Med J (Clin Res Ed); 1988 Jan; 296(6615):109-10. PubMed ID: 3122945
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacology in the United Kingdom.
    Smith RN
    Clin Pharmacol Ther; 1974 Sep; 16(3):605-15. PubMed ID: 4412474
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
    Gostin LO
    JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing the safety of medicines.
    Mansel-Jones D
    J R Coll Gen Pract; 1973 Jun; 23 Suppl 2(Suppl 2):67-70. PubMed ID: 4766237
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacovigilance in the framework of recording and control of drugs in the United Kingdom].
    Dunlop D
    Therapie; 1974; 29(6):799-804. PubMed ID: 4462229
    [No Abstract]   [Full Text] [Related]  

  • 17. Communicating adverse drug reactions.
    Lancet; 1978 Jan; 1(8056):133. PubMed ID: 87560
    [No Abstract]   [Full Text] [Related]  

  • 18. New law in Germany compensates patients for drug side-effects.
    Orellana C
    Lancet; 2002 Aug; 360(9331):471. PubMed ID: 12241734
    [No Abstract]   [Full Text] [Related]  

  • 19. The HEALTH Act's FDA defense to punitive damages: a gift to drug makers or to the public?
    Levy E
    Fordham Law Rev; 2006 Mar; 74(4):2425-60. PubMed ID: 17115481
    [No Abstract]   [Full Text] [Related]  

  • 20. [Intensified drug control--with drawbacks?].
    Böttiger LE
    Lakartidningen; 1983 Feb; 80(7):575-81. PubMed ID: 6855371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.